Daily Judi: Monday, November 21, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Japanese pharmaceutical company, Eisai, announced via press release it will reveal full findings of its new Alzheimer's drug lecanemab. Developed in partnership with Biogen, lecanemab showed promising topline clinical trial results this past September. The findings will be presented at the Clinical Trials on Alzheimer's Disease conference in San Francisco, CA, on November 29.
Megan Hollasch interviews Faith Mutale, DNP, CRN, on the integral role nurses can play in increasing equity in oncology clinical trials. (Oncology Nursing News)
In consideration of COVID-19, seasonal flu, and RSV, the Los Angeles Times offers tips on staying safe this holiday season.
Our Culture
“The Judi platform is purpose-built to drive clinical trial success—cloud-based, secure, collaborative. Our greatest strength, above all else, is our people.”
–Abraham Gutman, President & CEO
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
